Sonja Kagerer

Dr. Sonja Kagerer

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2025 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
SKSonja Kagerer
Sonja Kagerer
LVLaetitia Vionnet
Laetitia Vionnet
JBJiri M. G. van Bergen
Jiri M. G. van Bergen
RMRafael Meyer
Rafael Meyer
AGAnton F. Gietl
Anton F. Gietl
PUPaul G. Unschuld
Paul G. Unschuld
Introduction: The entorhinal cortex (EC)-hippocampus system is critical for memory and affected early in Alzheimer’s disease (AD). Cognitive dysfunction in AD is linked to neuropathological changes, including non-heme iron accumulation in vulnerable brain regions. This study characterized iron distribution in the EC-hippocampus system using ultra-high field (UHF) magnetic resonance imaging (MRI) at 7 Tesla (T) in aging and mild cognitive impairment (MCI), an AD at-risk state.Methods: 40 participants (mean age [SD] 69.2 [7.42] years; 12 mild cognitive impairment (MCI), 28 cognitively healthy controls (HC)) underwent UHF MRI at 7 T with turbo spin echo and quantitative susceptibility mapping (QSM). Gray matter segmentation was performed using FreeSurfer software. Intraclass correlation coefficients (ICCs) were calculated for hippocampal and EC measures.Results: ICCs for mean susceptibilities were 0.61 overall, 0.58 for HC, and 0.69 for MCI, with significant group differences between HC and MCI (Kolmogorov–Smirnov test, k = 0.625, p ≤ 0.05).Discussion: Our findings suggest a higher coherence of non-heme iron distribution in MCI. An increasingly uniform distribution of iron in MCI could reflect a clinical continuum ranging from healthy aging to pathologic brain change and cognitive disorder. This highlights the potential of non-heme iron as a biomarker for early AD co-pathology.

26 October 2025 in Journal of General and Family Medicine
Verified
Journal Article
Open access
MEMohamed Eshmawey
Mohamed Eshmawey
SKSonja Kagerer
Sonja Kagerer
FRFederica Ribaldi
Federica Ribaldi
AFAïda B. Fall
Aïda B. Fall
PUPaul Gerson Unschuld
Paul Gerson Unschuld
Background: Subjective cognitive decline (SCD) is characterized by the perception of cognitive dysfunction, and it could be one of the early signs of dementia. While SCD is a common phenomenon in old persons, little is known about how it affects interpersonal relationships. Methods: We conducted a cross‐sectional study involving 16 patients with SCD and 39 volunteers recruited from the COSCODE study. The Hazan and Shafer questionnaires were used to assess patients' attachment styles. The Experience in Close Relationships Scale was used to assess individual differences in attachment‐related anxiety and attachment‐related avoidance. A Wilcoxon rank‐sum test was performed to test for differences between groups, and p ‐values were Bonferroni‐corrected. Results: SCD is associated with lower disorganized attachment scores ( p = 0.01). SCD was not associated with experience in close relationships. Conclusion: Coping with progressive cognitive decline is a difficult mission. The results of our study on persons with SCD help us to better understand changes in couple relationships before the onset of dementia.

UNUmberto Nencha
Umberto Nencha
MEMohamed Eshmawey
Mohamed Eshmawey
DADaniele Altomare
Daniele Altomare
BMBoccardi Marina
Boccardi Marina
LSLeonardo Sacco
Leonardo Sacco
SKSonja Kagerer
Sonja Kagerer
Alzheimer’s disease has recently been redefined as a complex clinical–biological entity by the International Working Group (IWG), and while the cognitive symptoms associated with the disease progression have been thoroughly investigated, subtle behavioral changes that precede functional decline have been less systematically explored. Mild Behavioral Impairment has recently emerged and been operationalized with a dedicated checklist (MBI-C) to identify individuals presenting later-life persistent behavioral changes that might represent the first clinical signs related to an underlying neurodegenerative process. Here, we review current evidence supporting MBI as a promising clinical marker along the Alzheimer’s disease (AD) continuum since its preclinical stages, and we call for further research to investigate the potential added clinical value of a more structured, systematic assessment of behavioral changes in individuals at risk of progression. We outline that a structured MBI assessment could therefore be integrated first into future research diagnostic frameworks and, once validated in real-world settings, into routine clinical workups. Assessing MBI could then become a cost-effective, non-invasive tool aiding in distinguishing early neurodegenerative from primarily psychiatric disorders.